The assessment scope is based on the therapeutic indication(s) of the medicinal product. Therefore, with a view to enabling the subgroup on joint clinical assessments (‘the JCA Subgroup’) to update the assessment scope where deemed appropriate, while preserving the separation of the respective remits of the Coordination Group and the European Medicines Agency, the European Medicines Agency should inform the HTA secretariat on substantial questions or outstanding issues that might impact the therapeutic indication(s) proposed by the applicant for the medicinal product subject to a joint clinical assessment.
Recital 8, Regulation (EU) 2024/1381
In forcesince 23 May 2024